Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Futura MedicalFAMDF Return-on-Tangible-Equity is -168.69% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Futura Medical ranks worse than 84.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Futura Medical's annualized net income for the quarter that ended in Dec. 2025 was $-6.65 Mil. Futura Medical's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $3.94 Mil. Therefore, Futura Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -168.69%.
The historical rank and industry rank for Futura Medical's Return-on-Tangible-Equity or its related term are showing as below:
FAMDF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -530.4 Med: -87.34 Max: 17.91
Current: -183.69
During the past 13 years, Futura Medical's highest Return-on-Tangible-Equity was 17.91%. The lowest was -530.40%. And the median was -87.34%.
FAMDF's Return-on-Tangible-Equity is ranked worse than 84.4% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs FAMDF: -183.69
Futura Medical (OTCPK:FAMDF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Futura Medical Return-on-Tangible-Equity Related Terms
Futura Medical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Futura Medical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FAMDF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Futura Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Futura Medical Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Futura Medical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Futura Medical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -168.69% mean?
Futura Medical (FAMDF) has a Return-on-Tangible-Equity of -168.69% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Futura Medical and its competitors. According to the industry distribution chart, Futura Medical ranks #1012 out of 1199 companies in the Biotechnology industry, placing it in the top 84.4%.
Is Futura Medical's Return-on-Tangible-Equity too high?
Futura Medical's current Return-on-Tangible-Equity is -168.69%. Based on the distribution chart, Futura Medical ranks #1012 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Futura Medical's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #1012 out of 1199 companies for Return-on-Tangible-Equity. This places Futura Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Futura Medical and its competitors. Futura Medical's current Return-on-Tangible-Equity is -168.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FAMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.01 — trading 87.5% below its estimated fair value. The current Return-on-Tangible-Equity is -168.69%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Futura Medical (FAMDF), the current Return-on-Tangible-Equity is -168.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FAMDF has been successfully added to your 
